Faecal Calprotectin Testing in Primary Care
– Commissioners’ Guide to Implementation

A new national care pathway to help clinicians to simply and accurately distinguish between patients with Irritable Bowel Syndrome (IBS) and patients with Inflammatory Bowel Disease (IBD) has been developed.

The new pathway encourages primary care clinicians to use faecal calprotectin testing as a decision diagnostic. Evidence suggests that implementing a faecal calprotectin test in primary care reduces diagnostic uncertainty for patients as well as the number of unnecessary hospital referrals for further invasive and unpleasant diagnostic treatment.

We have spoken to CCGs and they have shared the benefits that can be achieved along with hints and tips to support the implementation of the new pathway.

Benefits of Implementation

<table>
<thead>
<tr>
<th>Patients</th>
<th>GPs</th>
<th>CCGs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improvement of patient experience leading to greater confidence in their diagnosis.</td>
<td>Reduction in the number of GP referrals to secondary specialist care.</td>
<td>Improved value for money resulting in financial savings.</td>
</tr>
<tr>
<td>Quicker diagnosis and treatment decisions will help early identification of serious conditions.</td>
<td>Gives clinicians more confidence in diagnosis without the need for secondary care intervention.</td>
<td>Reduction in unnecessary referrals will mean a reduction in number of patients attending outpatient appointments prior to procedures.</td>
</tr>
<tr>
<td>Integration of pathways to ensure that patients are seen in the right place, by the right person, at the right time.</td>
<td>Guidance will provide clinicians with a mechanism to guide the management and referral of patients.</td>
<td>May result in reduced waiting times for secondary care procedures.</td>
</tr>
</tbody>
</table>
**Guidance on Engagement and Implementation**

- A clinical champion is key to drive implementation and to help collaboration between Trust and CCG.
- Early engagement and education with stakeholders (i.e. GPs / patients / consultants / pathology lab) is vital for successful implementation.
- Engagement with the local AHSN network is essential in supporting implementation and roll out.
- Work with NHS Business Services Authority Pacific Team to help understand how to measure and evaluate benefits that can be achieved.
- Access supporting materials and support via your local AHSN and NHSBSA Pacific Team.

**Guidance on Post-Implementation Support**

- Ensuring GPs have confidence in the pathway instils patient confidence in their diagnosis.
- Encourage peer support - clinician to clinician meetings to help answer any questions.
- Use clinical systems (i.e EMIS) to help develop understanding of the pathway and how it is implemented.

For further information please contact:

- **Pacific Team at** [nhsbsapacificideas@nhs.net](mailto:nhsbsapacificideas@nhs.net)
- **Twitter:** [@NhsbsaPacific](https://twitter.com/NhsbsaPacific)

NHSBSA’s Pacific Team is helping deliver sustainability for the NHS by identifying, developing and delivering opportunities which create financial savings for reinvestment back into the NHS, enhance health and wellbeing and improve the quality of patient care.